What is lhrh analogue

FDA Resources. Arms and Interventions. Undergo orchiectomy or receive LHRH analogue therapy. Outcome Measures. Will be estimated with standard Kaplan-Meier K-M methodology. Will be estimated with standard K-M methodology. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Inclusion Criteria: Histologically confirmed prostate adenocarcinoma with metastasis either starting or recently started on LHRH analogue therapy.

If patients are on antiandrogen, this will need to be discontinued for at least 7 days prior to registration. Patients with a history of prior neoadjuvant or adjuvant hormone therapy are eligible provided they have received twenty four or less months of hormone treatment single or combination treatment, excluding orchiectomy. This is intended to exclude patients who might have been rendered indirectly androgen insensitive. There must be no plans to receive concomitant chemotherapy, biological response modifiers, radiation therapy or hormonal therapy.

Prior or concomitant use of megestrol acetate for the treatment of hot flashes is allowed. Patients must have a performance status of 0 - 2 by Zubrod Criteria. No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, superficial or in situ cancer of the bladder.

For an invasive cancer the patients should be disease free for at least 3 years prior to enrollment on study. For all patients a bone scan must be performed within 60 days prior to registration for tumor assessment.

CT scans abdomen and pelvis and chest x-ray are optional, but must be repeated if used for disease assessment. For late induction registrations, tumor assessment imaging showing metastatic disease must be available prior to start of androgen deprivation therapy.

Age 18 or older and willing and able to provide informed consent. Willingness to swallow pills and no medical condition that would interfere with this. Male patient and his female partner who is of childbearing potential must use 2 acceptable methods of birth control one of which must include a condom as a barrier method of contraception starting at screening and continuing throughout the study period and for 3 months after final study drug administration.

Patients are also required to use a condom if having sex with a pregnant woman. Patient should agree to a tumor tissue biopsy prior to protocol enrollment. Post therapy biopsy is optional. Prior chemotherapy for metastatic disease. Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Advanced search. Skip to main content Thank you for visiting nature.

Download PDF. Abstract Analogues of luteinising hormone releasing hormone LHRH have recently been introduced as an alternative to surgical orchidectomy in prostate cancer, but there has been concern about the economic costs of long-term treatment. You have full access to this article via your institution. View author publications. Rights and permissions Reprints and Permissions. The valuable role of LHRH analogues in the treatment of endometriosis has been established and, as newer formulations become available, they are likely to play an increasingly important part in patient management.

Abstract The induction of a state of hypo-oestrogenism has been found to be effective in the treatment of endometriosis. Publication types Comparative Study Review.